Mr. Wu holds a bachelor's degree in economics and a master's degree in business administration from Shanghai Jiaotong University. He is currently a PhD candidate at Tsinghua University. He has extensive contacts and more than 20 years of experience in the fields of domestic and international capital market operations, pharmaceutical. industry strategic development, mergers and acquisitions, business development and financial management. Prior to joining Sinopharm Group, Mr. Wu served as the financial controller of Weiwei (600300) and participated in the A-share listing of Weiwei. After joining Sinopharm Group in 2003, Mr. Wu served as the chief financial officer, deputy general manager and secretary-general of Sinopharm Holding (HK 1099), and served as a director of Concord Pharmaceutical (000028) and Sinopharm (600511). He has played an important role in the restructuring, mergers and acquisitions, listing operations and business operations of Sinopharm Group: responsible for the listing of H-shares of Sinopharm Holding; the share reform and restructuring of Sinopharm and Sinopharm; as the investment manager of Sinopharm, responsible for nearly 20 The investment decision-making, execution, and post-investment business restructuring of the remaining investment acquisition projects.
